TYVASO Inhalation Solution Offered for Pulmonary Arterial Hypertension

 

July 31, 2009

TYVASO (treprostinil) Inhalation Solution is indicated for the treatment of pulmonary arterial hypertension (PAH) using the TYVASO Inhalation System. TYVASO is indicated to increase walking distance in patients with NYHA Class III symptoms associated with WHO Group I PAH, which includes multiple etiologies such as idiopathic and familial PAH as well as PAH associated with scleroderma and congenital heart disease.

In The most common side effects seen with TYVASO in the placebo controlled clinical study were cough, headache, nausea, dizziness, flushing, throat irritation, pharyngolaryngeal pain and diarrhea.

TYVASO received FDA approval in July 2009.

For more information www.unither.com

The content of this field is kept private and will not be shown publicly.
By submitting this form, you accept the Mollom privacy policy.